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ABSTRACT 
PURPOSE: The popularity of germline genetic panel testing has led to a vast 
accumulation of variant-level data. Variant names are not always consistent across 
laboratories and not easily mappable to public variant databases such as ClinVar. A tool 
that can automate the process of variants harmonization and mapping is needed to help 
clinicians ensure their variant interpretations are accurate. 
METHODS: We present a Python-based tool, Ask2Me VarHarmonizer, that 
incorporates data cleaning, name harmonization, and a four-attempt mapping to ClinVar 
procedure. We applied this tool to map variants from a pilot dataset collected from 11 
clinical practices. Mapping results were evaluated with and without the transcript 
information. 
RESULTS: Using Ask2Me VarHarmonizer, 4728 out of 6027 variant entries (78%) were 
successfully mapped to ClinVar, corresponding to 3699 mappable unique variants. With 
the addition of 1099 unique unmappable variants, a total of 4798 unique variants were 
eventually identified. 427 (9%) of these had multiple names, of which 343 (7%) had 
multiple names within-practice. 99% mapping consistency was observed with and 
without transcript information.  
CONCLUSION: Ask2Me VarHarmonizer aggregates and structures variant data, 
harmonizes names, and maps variants to ClinVar. Performing harmonization removes 
the ambiguity and redundancy of variants from different sources.  
 
KEYWORDS: Germline variants; Genetic testing reports; Cancer; HGVS; ClinVar  
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INTRODUCTION 
With the widespread use of high-throughput sequencing and the rapid reduction in cost 
of genetic testing, the number of identified genetic variants has grown. Clinicians 
ordering genetic testing receive results on a large number of germline variants for a 
large number of patients. As new data accumulates, genetic variant interpretations may 
change:  variants of unknown significance (VUS) can change to benign or pathogenic, 
and even pathogenic variants can change to benign.1-3 It is therefore of utmost 
importance for genetic testing labs and physicians to regularly check their existing 
genetic variant classifications against a publicly available database (e.g., ClinVar) and 
other sources, to keep their interpretations up to date and inform patients of changes.  
Three major challenges must be overcome to accomplish this task. First, it is not 
feasible for labs or clinicians to manually map variants to existing variant databases, as 
the number of variants is extremely large. Second, inconsistencies exist in variant 
representations, especially in genetic reports released before the Human Genome 
Variation Society (HGVS) nomenclature guidelines4 became standard. Multiple naming 
conventions exist and the same variant can be denoted in several ways by different labs. 
For example, BRCA1 (NM_007294.3) variant c.68_69delAG is also recorded as 
185delAG or 187delAG; BRCA1 (NM_007294.3) variant c.181T>G is also recorded as 
300T>G. No simple approach exists to map existing naming conventions to a single 
harmonized name for each variant. Third, recording of variants is usually not in an 
accessible structured format limiting the usefulness of existing variant mapping tools. 
Genetic results are recorded in a variety of file formats, most of which, unfortunately, 
are not structured (e.g. portable document format (PDF) reports or electronic health 
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record (EHR) notes). Even when structured data is recorded, manual entry may result in 
recording the same variant in slightly different notations (e.g., c.68_69del, c68_69del, 
68_69del). This variation can render the variant unrecognizable by ClinVar or other 
databases. 
To address these challenges, we developed a Python-based tool, Ask2Me 
VarHarmonizer, that can be used to harmonize the different naming conventions of a 
unique variant into a single standardized name, automatically map it to a public variant 
archive, ClinVar, and return the naming and classification information. We applied this 
tool to a pilot variant dataset of more than 7000 variant submissions collected from 11 
clinical sites. 
MATERIALS AND METHODS 
Design of Ask2Me VarHarmonizer. Our implementation is in two steps: 1) curating 
and preprocessing the original variant entries; 2) harmonizing variants and mapping to 
ClinVar. The workflow is summarized in Fig 1 and described next through an example 
dataset. 
Step 1: Variant curating and preprocessing  
We collected original variant entries from participating practices using a common data 
collection form, with four required fields: “practice”, “gene”, “original variant name”, and 
“original lab-reported classification”, and four optional fields: “protein change”, “transcript 
ID”, “lab”, and “test year”. Definitions and examples for each field are in Table 1. 
The preprocessing steps include: (1) removal of incomplete variant entries: entries with 
missing or invalid information in at least one of the four required fields were removed 
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(e.g. no data or “0” in the “original variant names” field, or no data or “?” in the “original 
lab classification” field); (2) optional filtering of genes according to user defined criteria: 
this allows focusing on subsets of interest (e.g. cancer susceptibility genes). 
Variants from lab reports are usually classified into five categories: benign, likely benign, 
VUS, likely pathogenic, and pathogenic. First, we consolidated the variant 
classifications into three categories (referred to as “lab-reported classifications”): benign, 
VUS, and pathogenic. This was done to emphasize major differences in classification 
for the same variant, (e.g., pathogenic and VUS) and de-emphasize minor differences, 
which are likely to have less clinical significance (e.g., benign and likely benign). Details 
regarding the classification consolidation are provided in Table S1. Next, we removed 
duplicate entries, defined as any two variants having identical data in all the following 
fields: 1) “practice”, 2) “gene”, 3) “original variant name”, and 4) “lab-reported 
classification”.  
Step 2: Variant harmonizing and mapping to ClinVar 
We next mapped the variants to ClinVar to determine a single name for variants 
reported in multiple ways. We used the Entrez Direct application programming 
interface (API) to retrieve ClinVar5 data.  
The entire mapping process includes up to four mapping attempts, described below. 
First attempt: A combination of “gene”, “original variant name”, and “transcript ID” (if 
available) was submitted to the API. If ClinVar uniquely recognizes this variant, a 
response is obtained. The preferred ClinVar variant name was stored in a new field 
called “master variant name”. Similarly, the corresponding ClinVar classification was 
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also added and stored as a new field titled “ClinVar classification” (Fig 1, M1). Second 
attempt: For variants not mapped in the first attempt, the tool corrected the “original 
variant name” and stored the resulting correction in a new field labeled “corrected 
variant name”. In this process, the HGVS nomenclature was used as the standard 
naming convention. Corrections include but are not limited to (1) correcting basic 
typographical errors and omissions; (2) standardizing the use of “c.” (or “p.”) before 
each variant name; and (3) harmonizing deletions and insertions. For example, use of 
“c.” before DNA sequence varies, with “original variant name” sometimes listed as “c.” 
or omitting “c.”. For consistency, we confirmed or added “c.” before each variant name 
(e.g., correct “original variant name” for BRCA2 variant from 6895A>G to “corrected 
variant name”: c.6895A>G). We also harmonized deletions to the HGVS convention 
(e.g., changed “original variant name” for MSH6 variant from c.3699del4 to “corrected 
variant name”: c.3699_3702del). We then submitted a combination of “gene”, “corrected 
variant name”, and “transcript ID” (if available) to the API. If ClinVar uniquely recognized 
this variant, a response was obtained and recorded as described in the first attempt (Fig 
1, M2). Third attempt: For variants not mapped in the first or second attempts that 
have information on “protein change”, we submitted the combination of “gene”, 
“corrected variant name”, “protein change” and “transcript ID” (if available) to the API. If 
ClinVar uniquely recognized this variant, a response was obtained and recorded as 
described in the first attempt. Variant entries without “protein change” information were 
considered unmappable, and their “corrected variant names” were stored in the “master 
variant names” field (Fig 1, M3). Fourth attempt: For those variants that had “protein 
change” information but were unmappable in the third attempt, we removed the 
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“corrected variant name” from the query and attempted to remap them with the 
combination “gene”, “protein change”, and “transcript ID” (if available). Some “corrected 
variant names” may have been inaccurate and removing this field from the submission 
allowed us to attempt to map these variants. “master variant names” and “ClinVar 
classifications” were stored for the mappable variants, while the unmappable ones were 
considered unmappable, and their “corrected variant names” were stored in the “master 
variant names” field (Fig 1, M4). 
Eventually, we populate the “master variant names” field for all variants, either from 
ClinVar or from “corrected variant names”. Code for this mapping procedure is available 
upon request. 
Evaluating the impact of transcript reference sequence. As the transcript reference 
sequence associated with a variant may not always be available, we validated the 
impact of missing transcript reference sequences, by selecting a subset of variants with 
known “transcript ID”, and comparing the mapping results with and without “transcript 
ID”.  
Identifying unique variants and assessing multiple names. We defined a unique 
variant as a variant entry with unique “gene” and “master variant name” combination. 
Some unique variants appeared multiple times in the dataset, with differing “original 
variant name” (e.g. “CHEK2: c.470T>C” had two “original variant names”: “c.470T.C” in 
one practice and “c.470T)C” in another). We refer to these variants as those having 
multiple names. Unique variants with multiple names within a single practice are 
referred to as having within-practice multiple names (e.g. “MUTYH: c.1187G>A” has 
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“original variant names”: “1187G>A”, “c.1187G)A”, and “c,1187G>A” in the same 
practice).  
Evaluating the association between mappable rate and total number of variants in 
ClinVar. To evaluate the association between the mappable rates for unique variants 
(proportion of unique mappable variants of a gene) and the total number of variants in 
ClinVar, we graphed the mappable rate versus number of variants in ClinVar for all 
genes and performed a Poisson regression.  
Application. We collected a pilot dataset of variants from various clinical practices. 
Eleven clinical practices participated in this pilot, including Advanced Surgical Care of 
Northern Illinois; Advocate Health Care, Barrington, IL; Bermuda Cancer Genetics and 
Risk Assessment Clinic, Bermuda; The Breast Health and Wellness Center, Grand 
Rapids, MI; Comprehensive Breast Care, A Division of Michigan Healthcare 
Professionals, Troy, MI; Johns Hopkins Hospital (Euhus practice), Baltimore, MD; 
Massachusetts General Hospital (Hughes practice), Boston, MA; Nashville Breast 
Center, Nashville, TN; New Mexico Comprehensive Breast Care, Albuquerque, NM; 
Newton-Wellesley Hospital, Newton, MA; Texas Oncology, Austin, TX.  
We applied the developed Ask2Me VarHarmonizer to this pilot dataset, limiting the 
analysis to the 49 most commonly tested germline cancer susceptibility genes and/or 
genes with more than 5 variants reported in the pilot dataset: APC, ATM, BAP1, BARD1, 
BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, 
DIS3L2, EPCAM, FANCC, FH, FLCN, HOXB13, MEN1, MLH1, MRE11, MSH2, MSH6, 
MUTYH, NBN, NF1, NF2, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, 
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RAD51D, RB1, RECQL4, RET, SDHA, SDHB, SMAD4, SMARCA4, STK11, TP53, 
TSC1, TSC2, and VHL. 
The Dana-Farber Cancer Institute (DFCI) Institutional Review Board (IRB) has 
determined this study does not constitute human subjects research, and consequently 
formal IRB review is not warranted (DFCI protocol ID: 19-101).   
RESULTS  
Variant preprocessing. In all, we collected 7496 variant entries in 132 genes from 11 
practices (test period: 1996--2019). We removed variant entries lacking information or 
contained invalid information in any required field (n=47). We also excluded an 
additional 530 variant entries in genes other than the 49 of interest, and 892 variant 
entries with data in the combination “practice”, “gene”, “original variant name”, and “lab-
reported classification”. A total of 6027 variant entries (80.4% of the total submission) 
entered the mapping process (Fig 2, Step 1). 
Variant harmonizing and mapping results. The 6027 variant entries selected in step 
1 underwent four attempts at variant harmonization and mapping (Fig 2, Step 2). Among 
the 437 variants that mapped to ClinVar in the second attempt, 423 were corrected by 
standardizing the use of the initial “c.” and “p.” and 77 were corrected by standardizing 
the format of deletions or insertions. The date of access to ClinVar was April 17, 2019. 
Overall, 4728 (78.4%) of the 6027 variant entries were eventually mappable to ClinVar, 
with their corresponding ClinVar names stored in the “master variant names” field. For 
the remaining 1299 (21.6%) unmappable variant entries, their “corrected variant names” 
were stored in the “master variant names” field. 
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Impact of the transcript reference sequence. Among the 6027 variant entries, 
transcript reference sequence information was available for 3206 (53.2%) variant 
entries. By comparing the mapping results for these 3206 variants with or without 
“transcript IDs”, we found that for 98.6% (3162 out of 3206) of the variants we obtained 
the same mapping results, suggesting our mapping results were robust even in the 
absence of transcript reference sequence. 
Unique variants and multiple names. Among the 6027 variant entries, there were 
4798 variants with unique “gene” and “master variant name” combinations (i.e., unique 
variants): 3699 (77.0%) mappable, and 1099 (23.0%) unmappable. (Fig 3). The five 
genes with the largest number of unique variants were: BRCA2 (n = 601), ATM (n = 
440), BRCA1 (n = 421), APC (n = 265), and MSH6 (n = 237). The number of unique 
variants for each gene is summarized in Table S2. Among all unique variants, 474 
(9.9%) were found at multiple practices (373 at 2 practices, 73 at 3 practices, and 28 at 
more than 3 practices). 427 (8.9%) unique variants had multiple names, 343 of which 
had within-practice multiple names.  
Association between mapping rate and ClinVar variants count for each gene. With 
the exception of EPCAM, all genes had a mappable rate greater than 0.6 (Fig 3). The 
mappable rate and total number of variants in ClinVar for each gene are shown in Fig 4 
(we excluded EPCAM as 0 out of 6 EPCAM variants were mappable).  
We fit a Poisson model regressing the total number of variants in ClinVar against the 
mapping rate for the remaining 48 genes. We found a significant negative association. 
The coefficient for the mapping rate is -2.68 (95% CI: -2.74, -2.61), implying that a 
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0.1 increase in mapping rate, corresponds on average to a decrease by 0.268 in the 
log count of the total number of variants in ClinVar. 
DISCUSSION 
We developed a python-based tool, Ask2Me VarHarmonizer, that harmonizes the 
naming of variants collected from clinical practices and maps these variants to ClinVar. 
We applied this tool to over 7000 variant reports collected from 11 clinical practices. Of 
the 6027 variants in 49 genes of interest, 4728 (78.4%) were successfully mapped to 
ClinVar. A total of 4798 unique variants were eventually identified, and 8.9% of them (n 
= 427) were found to have multiple names.  
Although there are many well-developed tools (Mutalyzer6, hgvs Python package7, 
VariantValidator8, etc.) that manipulate and validate naming of variants according to 
HGVS guidelines4, all of them require complete and correct information on variants, 
including transcript reference sequence and sequence change in HGVS format for 
parsing (e.g. “NM_000038.5:c.3920T>A”). However, in practice, variant data recorded 
by clinicians is not always well formatted and the transcript reference sequences are not 
always easily found in genetic testing reports, especially for variants tested before the 
standardized format was widely used. Hence, there is no simple, automatic way for 
clinicians to submit lists of variants that have been collected over a period of years to 
public databases and successfully acquire an updated interpretation of clinical 
significance for each variant.  
Our tool, which was developed specifically for handling variants collected from germline 
genetic testing reports, can address problems of multiple naming conventions and 
recording errors. There are two sources of variability in naming for variants that 
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clinicians have collected from lab reports. First, different labs may report different 
names for a unique variant, and the same lab may report multiple names for a unique 
variant over time. This may be the result of using different reference transcripts (e.g. 
NM_007294.3 (BRCA1): c.68_69delAG is also known as NM_007300.3 (BRCA1): 
c.66_67delAG) or different formatting standards. Second, clinicians may record a 
unique variant from two identical reports differently. This is very common in the variant 
data we collected (e.g. NM_007294.3 (BRCA1) variant c.68_69delAG was sometimes 
denoted as c,68_69delAG). These are considered typographical errors, and, other than 
this tool, none of the existing above-mentioned tools is equipped to correct such errors. 
During our variant name standardization step, before the second mapping attempt, our 
tool explicitly corrects various typographical errors that are commonly seen in clinicians’ 
records (e.g. correct CHEK2 (NM_007194.3) variant c.470T.C to c.470T>C) and 
harmonizes the variability from lab reports (e.g. correcting APC (NM_000038.5) variant 
426delAT to c.426_427delAT).  
Our results from the pilot dataset demonstrated that 69.3% (n = 4178) of variants can be 
mapped to ClinVar in the first attempt of our four-attempt mapping tool (Fig 2). For the 
remaining unmappable variants, their “original variant names” are likely to be 
nonstandard and therefore not recognized by ClinVar directly. Our tool automatically 
standardized the variant names to resolve the variabilities in variant naming, then 
mapped those standardized names (“corrected variant name”) to ClinVar. We found that 
7.3% (n = 437) of the total variants in the pilot dataset were mappable in our second 
attempt, showing that those variants were originally recorded in a less accurate, but 
correctable, format. For the remaining unmappable variants, we leveraged their protein-
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level change information, if available. Using this information, in addition to the DNA-level 
change, can further improve precision and accuracy by mapping 1.4% (n = 86) 
additional variants. Since the remaining unmappable variants may have severe 
typographical errors, incorrect formats, or lack information in the variant name, but still 
have well-formatted protein-level change information, by removing the “corrected variant 
name” from the query, an additional 0.4% (n = 27) variants became mappable.  
For the mappable variants, we were able to further standardize the naming and to 
aggregate unique variants to single ClinVar preferred names; for the unmappable 
variants, especially those reported multiple times by the same or different practices, our 
database can serve as a proxy for ClinVar, and eventually we hope to encourage the 
enrolled clinical practices to submit these variants to ClinVar. In our pilot dataset, 1299 
variant entries could not be mapped to ClinVar. Possible reasons for unsuccessful 
mapping include: 1) The variants were not submitted to ClinVar; 2) Ambiguity in the 
variant name that could not be uniquely recognized by ClinVar. e.g. “PMS2 
(NM_000535.6): c.2T>?”; 3) The variant name was not recorded in standard HGVS 
format: For example, BRCA1 (NM_007294.3): del exons 21-24; 4) There were 
typographical errors that cannot be corrected, e.g. “,” in the nucleotide location.  
In our study, we found that only half of the variant entries had transcript reference 
sequence information, though our validation test demonstrated that 98.6% of the time 
we obtained the same mapping results with or without the reference sequence. Our 
analysis showed that 9% of the unique variants we identified had multiple names. These 
differences in recording of variants make data consolidation challenging. Multiple 
patients in the same practice were found to have the same variant, but named 
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differently. It would be ideal for practices to know which patients have the same variant 
in a gene. Linking these individuals (if related) can help find relatives that might 
otherwise be missed and help determine which bloodline the variant came through. For 
future research, obtaining the maximum number of people with a variant from each 
practice will aid the determination of classification and penetrance. 
Our study also showed an inverse association between the mappable rate and the total 
number of variants in ClinVar. We conjecture that this inverse association may be 
associated with incomplete variant coverage in ClinVar. Although several commonly 
tested genes have been sequenced for decades, many variants, especially from legacy 
variants reports, were not submitted to ClinVar.  
Our tool will be especially useful for low-resource clinical practices seeking to re-
evaluate their variant reports at no cost. We will incorporate it into our clinical decision 
support tool, Ask2Me9 for clinician practices to submit lists of variants from genetic 
testing, and obtain a report with harmonized variant names, updated classifications from 
ClinVar, and comparison results with other practices. These comparison results will be 
important in understanding the clinical significance of the variants and may help variant 
reclassification. The discordance between classifications across practices is also 
important and has been discussed elsewhere (Yin K et al. Legacy Genetic Testing 
Results for Cancer Susceptibility: How Common Are Conflicting Classifications in a 
Large Variant Dataset from Multiple Practices?, unpublished).  
The intent of our method is not to provide final adjudication of variant names or 
classifications but rather to identify probable variant names and discrepancies in 
classification and report back to each practice, with the expectation that each practice 
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will then work with their lab or labs to adjudicate classifications. We hope that this will 
provide a feedback mechanism to increase our accuracy over time. 
Remaining challenges in our computational pipeline are mapping capacity and accuracy 
given the available variant data. We are constantly improving our mapping algorithm 
and hope to encourage the participating practices to add unsubmitted variants to 
ClinVar. 
The Ask2Me VarHarmonizer is designed to harmonize naming of variants across clinical 
practices and to map them to ClinVar. We expect that this tool will allow clinicians to 
harmonize their variant reports in an effective and efficient manner, to access the most 
up-to-date information from ClinVar, to identify discordant results that individual 
practices can adjudicate with their labs, and to record the variants in a more consistent 
and structured format, ultimately providing better care for patients. The current system 
that uses a variety of naming conventions runs the risk of inappropriately managing 
patients. Harmonization of naming conventions with our tool will increase the likelihood 
that a given patient with a given variant will be appropriately managed. 
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FIGURE LEGENDS 
Fig 1. Workflow and example input dataset of Ask2Me VarHarmonizer. M1-M4 
correspond to the four mapping attempts. P1 is the preprocessing step; P2-P4 are the 
three processes before M2-M4, respectively. The example input dataset only shows 
part of the input fields. 
Fig 2. Flow chart of variant preprocessing and mapping results. 
Fig 3. Summary of mapping results by gene. The x-axis includes the 49 genes in our 
dataset. The top panel represents the percentage of unique mappable variants for each 
gene; the bottom panel represents the count of unique variants for each gene. 
Fig 4. Relationship between the proportion of unique mappable variants in our database 
and count of ClinVar total variants for each gene (excluding EPCAM). Each dot 
represents a gene, there are 48 genes plotted. 
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Table 1. Data collection table  
 
a Optional fields 
 
 
 
Field Description Example 
Practice The institution, hospital, medical 
system or practice submitting variants 
Bermuda Cancer 
Genetics and 
Risk Assessment 
Clinic  
Gene HGNC gene symbol10  APC 
Original variant 
name 
Variant name recorded by that 
practice, mostly as HGVS DNA-level 
change 
c.665A>T 
Original lab-reported 
classification  
Classification reported by lab VUS 
Protein changea Effect of the variant, mostly as HGVS 
protein-level change 
p.Gln222Leu 
Transcript IDa Transcript reference sequence: 
RefSeq11 or Ensembl Transcript12  
NM_000038.5 
Laba Lab that performed the test Invitae 
Test yeara Year of test  2017 
Original data
Processed Data
P1
Mappable variants
Use “Preferred ClinVar variant 
name” as “Master variant name”
E
Y
N
Mappable variants
Use “Preferred ClinVar variant 
name” as “Master variant name”
Y
N
.Has protein change
information?
Unmappable variants
Use “Corrected variant name” as
“Master variant name”
N
Y
Mappable variants
Use “Preferred ClinVar variant 
name” as “Master variant name”
Y
N
Mappable variants
Use “Preferred ClinVar variant 
name” as “Master variant name”
Use “Corrected variant name” as
“Master variant name”
P4
Process 1
·  Remove incomplete variant entries
·  Filter genes according to user defined criteria
· Consolidate ”lab-reported classification”
·  Remove entries with duplicated “practice”, “gene”,  
“original variant  name”, and “lab-reported
classification” combinations
P1
P2 Process 2
·  Correct “original variant name” 
·  Replace “original variant name” with “corrected variant 
names” in the mapping query
E
P3 Process 3· Add “protein Change” in the mapping query
P4 Process 4· Remove “corrected variant name” from the mapping query
Mapping 1st attempt
Query: “gene”, “original variant name”, and “transcript ID” 
(if available)
M1
Mapping 2nd attempt
Query: “gene”, “corrected variant name”, and “transcript ID” 
(if available)
M2
Mapping 3rd attempt
Query: “gene”, “corrected variant name”, “protein change” 
and “transcript ID” (if available)
M3
Mapping 4th attempt
Query: “gene”, “protein change”, and “transcript ID” 
(if available)
M4
Extract name and classification
Information from ClinVar
P3
E
E
E Y
N
M1
M3
M4
M2
P2 ID Gene Original variant name Protein change Corrected variant name
3 APC c.1000G>A - c.1000G>A
5 APC c.2119C>T p.Leu707Phe c.2119C>T
6 APC c.222A>G p.N741S c.222A>G
7 APC c.4432A>T p.Gln1444His c.4432A>T
9 APC c.8203G>A p.Gly2735Arg c.8203G>A
11 BRCA1 c.247delC p.Asp825GlufsX21 c.247delC
ID Gene
Original
variant
name
Protein change Corrected variantname
Master variant
name (Preferred
ClinVar variant
name)
2 APC 7334A>G p.Lys2445Arg c.7334A>G c.7334A>G
4 APC c.147del4 - c.147_150del c.147_150delACAA
10 BARD1 c2306C>G - c.2306C>G c.2306C>G
14 CHEK2 c.470T.C - c.470T>C c.470T>C
15 CHEK2 c.470T)C - c.470T>C c.470T>C
ID Gene Originalvariant name
Protein
change
Master variant
name (Preferred
ClinVar variant
name)
1 APC 3920T>A - c.3920T>A
8 APC c.6918T>A p.Asp2306Glu c.6918T>A
12 BRCA2 2066T>G - c.1838T>G
13 BRCA2 999del5 - c.771_775delTCAAA
ID Gene Original variant name Protein change
2 APC 7334A>G p.Lys2445Arg
3 APC c.1000G>A -
4 APC c.147del4 -
5 APC c.2119C>T p.Leu707Phe
6 APC c.222A>G p.N741S
7 APC c.4432A>T p.Gln1444His
9 APC c.8203G>A p.Gly2735Arg
10 BARD1 c2306C>G -
11 BRCA1 c.247delC p.Asp825GlufsX21
14 CHEK2 c.470T.C -
15 CHEK2 c.470T)C -
ID Gene Original variant name Protein change
1 APC 3920T>A -
2 APC 7334A>G p.Lys2445Arg
3 APC c.1000G>A -
4 APC c.147del4 -
5 APC c.2119C>T p.Leu707Phe
6 APC c.222A>G p.N741S
7 APC c.4432A>T p.Gln1444His
8 APC c.6918T>A p.Asp2306Glu
9 APC c.8203G>A p.Gly2735Arg
10 BARD1 c2306C>G -
11 BRCA1 c.247delC p.Asp825GlufsX21
12 BRCA2 2066T>G -
13 BRCA2 999del5 -
14 CHEK2 c.470T.C -
15 CHEK2 c.470T)C -
ID Gene Originalvariant name
Protein
change
Corrected
variant
name
Master
variant name
(Corrected
variant name)
3 APC c.1000G>A - c.1000G>A c.1000G>A
ID Gene
Original
variant
name
Protein
change
Corrected
variant
name
Master
variant name
(Preferred
ClinVar
variant name)
7 APC c.4432A>T p.Gln1444His c.4432A>T c.4332A>T
9 APC c.8203G>A p.Gly2735Arg c.8203G>A c.8203G>C
ID Gene
Original
variant
name
Protein change Correctedvariant name
5 APC c.2119C>T p.Leu707Phe c.2119C>T
6 APC c.222A>G p.N741S c.222A>G
11 BRCA1 c.247delC p.Asp825GlufsX21 c.247delC
ID Gene
Original
variant
name
Protein change
Corrected
variant
name
Master
variant name
(Preferred
ClinVar
variant name)
6 APC c.222A>G p.N741S c.222A>G c.2222A>G
11 BRCA1 c.247delC p.Asp825GlufsX21 c.247delC c.2475delC
ID Gene
Original
variant
name
Protein change
Corrected
variant
name
Master
variant name
(Corrected
variant name)
5 APC c.2119C>T p.Leu707Phe c.2119C>T c.2119C>T
Unmappable variants
Fig 1. 
7,496 variant entries covering 
132 genes collected from 11 practices
7,449 variant entries covering 
132 genes
6,919 variant entries covering 
49 genes
47 variant entries 
lack/with invalid information in any 
required fields 
530 variant entries 
whose corresponding genes were not 
among above 49 genes of interest
892 duplicate variant entries
defined as all four fields, “practice”, “gene”, 
“original variant name”, and “lab-reported 
classification”, being identical 
4,178 variants that are
mappable in the 1st
attempt
1,849 variants that are unmappable
in the 1st attempt
437 variants that are
mappable in the 2nd
attempt
1,066 variants that do
not have “protein
change” information are
considered eventually
unmappable
6,027 variants covering 49 genes
1,412 variants that are unmappable
in the 2nd attempt
346 variants that have
“protein change” information
260 variants that are unmappable
in the 3rd attempt
86 variants that are
mappable in the 3rd
attempt
233 variants that are
unmappable
in the 4th attempt are
considered eventually
unmappable
27 variants that are
mappable in the 4th
attempt
Excluded
Excluded
Excluded
Step 1
Mapping 1st attempt
Mapping 2nd attempt
Mapping 3rd attempt
Mapping 4th attempt
Step 2
Total mappable variants = 4,728
Total unmappable variants = 1,299
Date of access to ClinVar: 4/17/2019
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